159 related articles for article (PubMed ID: 17915079)
1. Sleep disturbances and ADHD medications.
Rostain AL
Curr Psychiatry Rep; 2007 Oct; 9(5):399-400. PubMed ID: 17915079
[No Abstract] [Full Text] [Related]
2. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response.
Newcorn JH; Kratochvil CJ; Allen AJ; Casat CD; Ruff DD; Moore RJ; Michelson D;
Am J Psychiatry; 2008 Jun; 165(6):721-30. PubMed ID: 18281409
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.
Awudu GA; Besag FM
Drug Saf; 2014 Sep; 37(9):661-76. PubMed ID: 25124483
[TBL] [Abstract][Full Text] [Related]
4. Effects of atomoxetine and methylphenidate on sleep in children with ADHD.
Sangal RB; Owens J; Allen AJ; Sutton V; Schuh K; Kelsey D
Sleep; 2006 Dec; 29(12):1573-85. PubMed ID: 17252888
[TBL] [Abstract][Full Text] [Related]
5. Letter to the editor: Comment on 'Acute impact of immediate release methylphenidate administered three times a day on sleep in children with attention-deficit/hyperactivity disorder'.
Olders H
J Pediatr Psychol; 2009; 34(1):108-9; author reply 110-2. PubMed ID: 19136567
[No Abstract] [Full Text] [Related]
6. Pharmacological management of treatment-induced insomnia in ADHD.
Kratochvil CJ; Lake M; Pliszka SR; Walkup JT
J Am Acad Child Adolesc Psychiatry; 2005 May; 44(5):499-501. PubMed ID: 15843773
[No Abstract] [Full Text] [Related]
7. [My child is so restless].
Schlamp D
MMW Fortschr Med; 2007 Mar; 149(10):39-40. PubMed ID: 17408047
[TBL] [Abstract][Full Text] [Related]
8. Once-daily OROS methylphenidate is safe and well tolerated in adolescents with attention-deficit/hyperactivity disorder.
McGough JJ; McBurnett K; Bukstein O; Wilens TE; Greenhill L; Lerner M; Stein M
J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):351-6. PubMed ID: 16768642
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological treatment of attention-deficit/hyperactivity disorder in adults.
Slatkoff J; Greenfield B
Expert Opin Investig Drugs; 2006 Jun; 15(6):649-67. PubMed ID: 16732717
[TBL] [Abstract][Full Text] [Related]
10. [Long-acting medications for the treatment of hyperkinetic disorders - a systematic review and European treatment guidelines. Part 2: a quantitative evaluation of long-acting medications].
Banaschewski T; Coghill D; Santosh P; Zuddas A; Asherson P; Buitelaar J; Danckaerts M; Döpfner M; Faraone SV; Rothenberger A; Sergeant J; Steinhausen HC; Sonuga-Barke EJ; Taylor E
Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):97-106; quiz 106-7. PubMed ID: 18622939
[TBL] [Abstract][Full Text] [Related]
11. Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.
Eiland LS; Bell EA; Erramouspe J
Ann Pharmacother; 2014 Oct; 48(10):1350-5. PubMed ID: 24982313
[TBL] [Abstract][Full Text] [Related]
12. [Atomoxetine: a new treatment for Attention Deficit/Hyperactivity Disorder (ADHD) in children and adolescents].
Purper-Ouakil D; Fourneret P; Wohl M; Rénéric JP
Encephale; 2005; 31(3):337-48. PubMed ID: 16142049
[TBL] [Abstract][Full Text] [Related]
13. Comparative study of OROS-MPH and atomoxetine on executive function improvement in ADHD: a randomized controlled trial.
Yang L; Cao Q; Shuai L; Li H; Chan RC; Wang Y
Int J Neuropsychopharmacol; 2012 Feb; 15(1):15-26. PubMed ID: 22017969
[TBL] [Abstract][Full Text] [Related]
14. [Comment on the European guidelines for use of delayed action drugs for treatment of hyperkinetic disorders].
Banaschewski T; Döpfner M; Rothenberger A; Steinhausen H-
Z Kinder Jugendpsychiatr Psychother; 2008 Mar; 36(2):77-9. PubMed ID: 18622937
[No Abstract] [Full Text] [Related]
15. Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.
Wong IC; Asherson P; Bilbow A; Clifford S; Coghill D; DeSoysa R; Hollis C; McCarthy S; Murray M; Planner C; Potts L; Sayal K; Taylor E
Health Technol Assess; 2009 Oct; 13(50):iii-iv, ix-xi, 1-120. PubMed ID: 19883527
[TBL] [Abstract][Full Text] [Related]
16. Transdermal methylphenidate (Daytrana) for ADHD.
Med Lett Drugs Ther; 2006 Jun; 48(1237):49-51. PubMed ID: 16785850
[No Abstract] [Full Text] [Related]
17. ADHD update: new data on the risks of medication.
Harv Ment Health Lett; 2006 Oct; 23(4):3-5. PubMed ID: 17183739
[No Abstract] [Full Text] [Related]
18. Improving decision making in the treatment of ADHD.
Vitiello B
Am J Psychiatry; 2008 Jun; 165(6):666-7. PubMed ID: 18519529
[No Abstract] [Full Text] [Related]
19. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Adults With ADHD.
Ni HC; Lin YJ; Gau SS; Huang HC; Yang LK
J Atten Disord; 2017 Jan; 21(1):27-39. PubMed ID: 23475825
[TBL] [Abstract][Full Text] [Related]
20. Newly approved once-daily formulations of medications for the treatment of Attention Deficit (Hyperactivity) Disorder (ADHD) in children and adolescents.
Roman MW
Issues Ment Health Nurs; 2010 Aug; 31(8):548-9. PubMed ID: 20624025
[No Abstract] [Full Text] [Related]
[Next] [New Search]
